Gene description for ILF3
Gene name interleukin enhancer binding factor 3
Gene symbol ILF3
Other names/aliases CBTF
DRBF
DRBP76
MMP4
MPHOSPH4
MPP4
MPP4110
NF-AT-90
NF110
NF110b
NF90
NF90a
NF90b
NF90c
NF90ctv
NFAR
NFAR-1
NFAR-2
NFAR110
NFAR2
NFAR90
TCP110
TCP80
Species Homo sapiens
 Experiment description of studies that identified ILF3 in Chronic lymphocytic leukemia cells

1
Experiment ID901
Identified moleculeprotein
Extracellular vesicle typeExosomes
MISEVEVs
Identification method Mass spectrometry
PubMed ID 26100252   
OrganismHomo sapiens
Experiment descriptionExosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts
AuthorsPaggetti J, Haderk F, Seiffert M, Janji B, Distler U, Ammerlaan W, Kim YJ, Adam J, Lichter P, Solary E, Berchem G, Moussay E.
Journal name Blood
Publication year2015
SampleChronic lymphocytic leukemia cells
Sample nameJVM-3
Isolation/purification methodsDifferential centrifugation
Filtration
Ultracentrifugation
Density gradient centrifugation
Flotation density1.15-1.17 g/mL
Molecules identified in the studyProtein
Methods used in the studyMass spectrometry
EV-TRACK EV150015: EV-METRIC:22%, 44%

2
Experiment ID902
Identified moleculeprotein
Extracellular vesicle typeExosomes
MISEVEVs
Identification method Mass spectrometry
PubMed ID 26100252   
OrganismHomo sapiens
Experiment descriptionExosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts
AuthorsPaggetti J, Haderk F, Seiffert M, Janji B, Distler U, Ammerlaan W, Kim YJ, Adam J, Lichter P, Solary E, Berchem G, Moussay E.
Journal name Blood
Publication year2015
SampleChronic lymphocytic leukemia cells
Sample nameMEC-1
Isolation/purification methodsDifferential centrifugation
Filtration
Ultracentrifugation
Density gradient centrifugation
Flotation density1.15-1.17 g/mL
Molecules identified in the studyProtein
Methods used in the studyMass spectrometry
FACS
Western blotting
EV-TRACK EV150015: EV-METRIC:22%, 44%

<